Yize Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yize Li has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Li Ding
Washington University in St. Louis
24 shared publications - Reyka G. Jayasinghe
Washington University in St. Louis 4 Saint Louis, MO
15 shared publications - Julie K. Schwarz
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA
14 shared publications - Sherri R. Davies
Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA
14 shared publications - David G. DeNardo
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
12 shared publications - Ana Carolina Paschoalini Mafra
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications
Latest Publications
- Open Access
An Auto-RS Signature for Prognostic Stratification and Drug Sensitivity Prediction in Osteosarcoma
Background: Metastasis and poor chemotherapy response have stagnated therapeutic progress in osteosarcoma (OS) for the past three decades. Defining the transition from localized to metastatic OS before overt dissemination is fundamental for improving survival. However, effective early diagnostic tools remain scarce, largely due to limited exploitation of the metastasis-associated tumor microenvironment’s own record of prior environmental and stress exposures encoded in cell-intrinsic transcriptional states. Here, we employed a supervised machine learning framework with iterative resampling and multi-stage model selection to identify molecular markers associated with metastasis in osteosarcoma and to develop a computational signature, Auto-RS. Methods: Transcriptomic and clinical data from 139 OS patients with ≥5 years of follow-up were analyzed. A LASSO–Cox framework was applied to derive a gene expression-based risk score, Auto-RS, from which a nomogram integrating age and sex was generated for individualized prognosis. Model interpretability was assessed across six independent single-cell OS patient datasets, and drug sensitivity predictions were inferred by integrating Auto-RS with the Precily algorithm to uncover actionable therapeutic vulnerabilities. Results: Auto-RS, constructed from the expression of four autophagy genes (BNIP3, MYC, PEA15, and SAR1A), served as an independent prognostic factor for overall survival (HR = 1.091; 95% CI, 1.047–1.136; p < 0.001). Time-dependent ROC analysis showed that Auto-RS was the most accurate single predictor (AUC = 0.88), exceeding metastasis (0.83), sex (0.45), and age (0.39). A basic prognostic model (BpM) incorporating metastasis status yielded a C-index of 0.741 (95% CI, 0.679–0.803). The addition of Auto-RS (CpM) improved discrimination (C-index = 0.788; 95% CI, 0.731–0.845), whereas a model without metastasis information (ApM) retained predictive ability (C-index = 0.709; 95% CI, 0.640–0.778). Single-cell analysis confirmed that Auto-RS features aligned with known metastatic trajectories, reflecting the transition from proliferative to invasive tumor states and highlighting coordinated programs among cancer-associated fibroblasts and immune cells. Drug sensitivity integration through Precily identified gemcitabine and cytarabine as FDA-approved agents predicted in silico to show greater sensitivity in the high-risk subgroup. Conclusions: We identified autophagy-mediated transcriptional ‘stress fingerprints’ that are tightly associated with OS metastasis. The Auto-RS signature, composed of BNIP3, MYC, PEA15, and SAR1A, enables early therapeutic stratification of patients independent of overt metastatic status. Moreover, Auto-RS delineates key molecular underpinnings of OS metastasis at single-cell resolution. As a practical laboratory tool, Auto-RS may represent a step toward improved risk stratification, where advances in metastasis prediction and therapeutic guidance converge to improve outcomes in OS.
Open AccessAn Auto-RS Signature for Prognostic Stratification and Drug Sensitivity Prediction in Osteosarcoma
Background: Metastasis and poor chemotherapy response have stagnated therapeutic progress in osteosarcoma (OS) for the past three decades. Defining the transition from localized to metastatic OS before overt dissemination is fundamental for improving survival. However, effective early diagnostic tools remain scarce, largely due to limited exploitation of the metastasis-associated tumor microenvironment’s own record of prior environmental and stress exposures encoded in cell-intrinsic transcriptional states. Here, we employed a supervised machine learning framework with iterative resampling and multi-stage model selection to identify molecular markers associated with metastasis in osteosarcoma and to develop a computational signature, Auto-RS. Methods: Transcriptomic and clinical data from 139 OS patients with ≥5 years of follow-up were analyzed. A LASSO–Cox framework was applied to derive a gene expression-based risk score, Auto-RS, from which a nomogram integrating age and sex was generated for individualized prognosis. Model interpretability was assessed across six independent single-cell OS patient datasets, and drug sensitivity predictions were inferred by integrating Auto-RS with the Precily algorithm to uncover actionable therapeutic vulnerabilities. Results: Auto-RS, constructed from the expression of four autophagy genes (BNIP3, MYC, PEA15, and SAR1A), served as an independent prognostic factor for overall survival (HR = 1.091; 95% CI, 1.047–1.136; p < 0.001). Time-dependent ROC analysis showed that Auto-RS was the most accurate single predictor (AUC = 0.88), exceeding metastasis (0.83), sex (0.45), and age (0.39). A basic prognostic model (BpM) incorporating metastasis status yielded a C-index of 0.741 (95% CI, 0.679–0.803). The addition of Auto-RS (CpM) improved discrimination (C-index = 0.788; 95% CI, 0.731–0.845), whereas a model without metastasis information (ApM) retained predictive ability (C-index = 0.709; 95% CI, 0.640–0.778). Single-cell analysis confirmed that Auto-RS features aligned with known metastatic trajectories, reflecting the transition from proliferative to invasive tumor states and highlighting coordinated programs among cancer-associated fibroblasts and immune cells. Drug sensitivity integration through Precily identified gemcitabine and cytarabine as FDA-approved agents predicted in silico to show greater sensitivity in the high-risk subgroup. Conclusions: We identified autophagy-mediated transcriptional ‘stress fingerprints’ that are tightly associated with OS metastasis. The Auto-RS signature, composed of BNIP3, MYC, PEA15, and SAR1A, enables early therapeutic stratification of patients independent of overt metastatic status. Moreover, Auto-RS delineates key molecular underpinnings of OS metastasis at single-cell resolution. As a practical laboratory tool, Auto-RS may represent a step toward improved risk stratification, where advances in metastasis prediction and therapeutic guidance converge to improve outcomes in OS.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cytoscape node information related to Fig. 1l
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cytoscape node information related to Fig. 1l